JFG
SGMO

Jefferies Financial Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Jefferies Financial Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,600
Closed -$22.5K – 2152
2025
Q4 		$22.5K Hold
53,600
– – ﹤0.01% 1795
2025
Q3 		$36.1K Hold
53,600
– – ﹤0.01% 1397
2025
Q2 		$29K Hold
53,600
– – ﹤0.01% 1214
2025
Q1 		$35.2K Hold
53,600
– – ﹤0.01% 1529
2024
Q4 		$54.7K Buy
+53,600
New +$98K ﹤0.01% 1494

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jefferies Financial Group's SGMO Position: Q1 2026 in Review

Jefferies Financial Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 53,600 shares — an estimated $22.5K sold.

Jefferies Financial Group first reported a position in SGMO in Q4 2024 and held it in 5 quarters. The position peaked at $54.7K in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Jefferies Financial Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 53,600 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $22.5K.
  • Jefferies Financial Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and held it in 5 quarters.
  • Jefferies Financial Group's SANGAMO THERAPEUTICS INC position peaked at $54.7K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.